Free by publisher: Verlagsversion online verfügbar 01/2025
möglich sobald bei der ZB eingereicht worden ist.
Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.
Diabetes Care 47, 1276-1298 (2024)
DOI
PMC
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings. To inform this monitoring, JDRF, in conjunction with international experts and societies, developed consensus guidance. Broad advice from this guidance includes the following: 1) partnerships should be fostered between endocrinologists and primary care providers to care for people who are IAb+; 2) when people who are IAb+ are initially identified, there is a need for confirmation using a second sample; 3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; 4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; 5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and 6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasizes significant unmet needs for further research on early-stage type 1 diabetes to increase the rigor of future recommendations and inform clinical care.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Disease-modifying Therapy; Beta-cell Autoimmunity; 1st 2 Years; Clinical Characteristics; General-population; Environmental Determinants; Psychological Impact; Glycemic Control; Young-children; C-peptide
ISSN (print) / ISBN
0149-5992
e-ISSN
1935-5548
Zeitschrift
Diabetes Care
Quellenangaben
Band: 47,
Heft: 8,
Seiten: 1276-1298
Verlag
American Diabetes Association
Verlagsort
Alexandria, Va.
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes Research Type 1 (IDF)
Institute for Pancreatic Beta Cell Research (IPI)
Institute for Pancreatic Beta Cell Research (IPI)
Förderungen
JDRF International
Advanced Technologies & Treatments for Diabetes (ATTD)
American Association of Clinical Endocrinology (AACE)
American College of Diabetology (ACD)
American Diabetes Association (ADA)
Association of Diabetes Care & Education Specialists (ADCES)
Association for the Endocrine Society
Australian Diabetes Society (ADS)
European Association for the Study of Diabetes (EASD)
International Society for Pediatric and Adolescent Diabetes (ISPAD)
JDRF
Advanced Technologies & Treatments for Diabetes (ATTD)
American Association of Clinical Endocrinology (AACE)
American College of Diabetology (ACD)
American Diabetes Association (ADA)
Association of Diabetes Care & Education Specialists (ADCES)
Association for the Endocrine Society
Australian Diabetes Society (ADS)
European Association for the Study of Diabetes (EASD)
International Society for Pediatric and Adolescent Diabetes (ISPAD)
JDRF